TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05301452

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intravascular Irradiation of Blood (ILIB)
Description: The laser treatment will be performed by a speech therapist and will have the following parameters: wavelength of 808 nm. It will be done twice a week for 8 weeks, in 20-minute sessions.

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Intravascular Irradiation of Blood (ILIB)
Description: The photobiomodulation procedure will be simulated, but with the laser turned off. It will be done twice a week for 8 weeks, in 20-minute sessions.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Orofacial Myofunctional Therapy
Description: Myofunctional therapy will be performed by a speech therapist specialized in the area. It will consist of 1 weekly session, where the functions of breathing, chewing and swallowing will be evaluated and addressed.~The following exercises will be indicated: nasal hygiene, inflated cheeks with the tip of the tongue on the palate, lingual sweep, tongue thrust against the palate, tongue touch on the last molars, chewing of soft solids and bolus assembly (20 minute therapy session).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Orofacial Myofunctional Therapy
Description: Myofunctional therapy will be performed by a speech therapist specialized in the area. It will consist of 1 weekly session, where the functions of breathing, chewing and swallowing will be evaluated and addressed.~The following exercises will be indicated: nasal hygiene, inflated cheeks with the tip of the tongue on the palate, lingual sweep, tongue thrust against the palate, tongue touch on the last molars, chewing of soft solids and bolus assembly (20 minute therapy session).
Study: NCT05828745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB06-036
Description: CB06-036 capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB06-036
Description: CB06-036 capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB06-036
Description: CB06-036 capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB06-036
Description: CB06-036 capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule
Study: NCT05257174

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Jing Si Herbal Tea LIQUID PACKETS
Description: intake Jing Si Herbal Tea LIQUID PACKETS twice daily for three months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intake Placebo twice daily for three months
Study: NCT05912179

Intervention type: DIAGNOSTIC_TEST
Intervention: Liver biopsy - percutaneous
Description: liver biopsy obtained using percutaneous ultrasound guided technique

Intervention type: DIAGNOSTIC_TEST
Intervention: Liver biopsy - transjugular
Description: liver biopsy obtained using an interventional transjugular approach

Intervention type: DIAGNOSTIC_TEST
Intervention: liver biopsy - EUS guided
Description: liver biopsy obtained during endoscopic ultrasound
Study: NCT04986566

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Use standard reporting procedures

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Use standard reporting procedures

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education
Description: Use Aetonixx app

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Use Aetonixx app

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Wear Vivofit 4

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Device Usage and Evaluation
Description: Wear Vivofit 4

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Complete questionnaires

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Complete questionnaires
Study: NCT05975593

Intervention type: OTHER
Group type: OTHER
Intervention: Blood collection
Description: Cervical cancer: pre-radiation therapy, 1 week after beginning radiation therapy, 3 weeks after beginning radiation therapy, 6 weeks after completing radiation therapy, 12 weeks after completing radiation therapy, and recurrence.~Pancreatic cancer: pre-stereotactic body radiotherapy, 6 weeks after completion of radiotherapy, 12 weeks after completion of radiotherapy, surgery (if applicable), and recurrence
Study: NCT06542185

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: online education
Description: online education
Study: NCT05525637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YZJ-1139 20mg
Description: YZJ-1139 20mg tablets, once daily in the evening

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YZJ-1139 40mg
Description: YZJ-1139 40mg tablets, once daily in the evening

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Match placebo tablets, once daily in the evening
Study: NCT05975593

Intervention type: OTHER
Group type: OTHER
Intervention: Blood collection
Description: Cervical cancer: pre-radiation therapy, 1 week after beginning radiation therapy, 3 weeks after beginning radiation therapy, 6 weeks after completing radiation therapy, 12 weeks after completing radiation therapy, and recurrence.~Pancreatic cancer: pre-stereotactic body radiotherapy, 6 weeks after completion of radiotherapy, 12 weeks after completion of radiotherapy, surgery (if applicable), and recurrence

Intervention type: DEVICE
Group type: OTHER
Intervention: Diffusion basis spectrum imaging (DBSI) magnetic resonance imaging (MRI)
Description: Cervical cancer: initial staging, 12 weeks after completing radiation therapy, and recurrence.~Pancreatic cancer: initial staging, stereotactic body radiotherapy (SBRT) simulation, 12 weeks after completing radiation therapy, and recurrence.~The imaging will be performed when possible.

Intervention type: DEVICE
Group type: OTHER
Intervention: Diffusion basis spectrum imaging (DBSI) magnetic resonance imaging (MRI)
Description: Cervical cancer: initial staging, 12 weeks after completing radiation therapy, and recurrence.~Pancreatic cancer: initial staging, stereotactic body radiotherapy (SBRT) simulation, 12 weeks after completing radiation therapy, and recurrence.~The imaging will be performed when possible.
Study: NCT04970966

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PuraSinus
Description: A randomized ethmoid cavity in the patient will have PuraSinus applied to the ethmoid cavity after completion of an endoscopic total ethmoidectomy.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bioresorbable Nasal Dressing
Description: PosiSep X will be applied to the ethmoid cavity after completion of an endoscopic total ethmoidectomy.
Study: NCT05543616

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose
Description: Injection in the muscle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Variant-adapted BNT162b2 (Omicron XBB.1.5) Substudy A Ph 2/3 Selected Dose
Description: Injection in the muscle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Variant-adapted BNT162b2 (Omicron XBB.1.5) Substudy A Ph 2/3 Selected Dose
Description: Injection in the muscle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Variant-adapted BNT162b2 (Omicron XBB.1.5) Substudy A Ph 2/3 Selected Dose
Description: Injection in the muscle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Variant-adapted BNT162b2 (Omicron XBB.1.5) Substudy A Ph 2/3 Selected Dose
Description: Injection in the muscle
Study: NCT06640426

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Two Messaging Nudges
Description: This intervention involves receiving one personalized email and one personalized text message, which include the provider's name, the patient's name, and a phone number to schedule an Annual Wellness Visit

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Five messaging nudges
Description: This intervention involves patients receiving up to five personalized email and text messages, which include the provider's name, the patient's name, and a phone number to schedule an Annual Wellness Visit
Study: NCT04662320

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Checkpoint BEST System
Description: Single use medical device, consisting of electric stimulator and intraoperative lead. Therapy consists of single, 10 minute dose delivered proximal to site of decompression/repair.~Other Name: Checkpoint BEST System
Study: NCT06030258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN10018
Description: orally taken once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tislelizumab
Description: 200mg D1, Q3W, intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200mg D1, Q3W, intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: AUC 5 mg/ml/min, D1, Q3W, intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5 mg/ml/min, D1, Q3W, intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Etoposide 100 mg/m2, D1-D3, Q3W, intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 100 mg/m2, D1-D3, Q3W, intravenously
Study: NCT06102538

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: # The importance of service in the IDF # Physical activity # Healthy nutrition # Psychological support
Description: # Education for the importance of service in the IDF # Education and training for physical activity adapted to abilities # Training for a healthy diet # Psychological support
Study: NCT04631341

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Melatonin 5mg every night, for one year
Study: NCT06191419

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Odorants
Description: Each smoker is assigned a CPAP nose mask. Odor sample bags are attached to the mask. Smokers open the valve, inhale once through the nose, close the valve, remove the bag from the mask and report on the odor.
Study: NCT06510946

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: (Health education program) To increase therapeutic adherence in patients with secondary prevention for cardiovascular disease
Description: The intervention involves a comprehensive health education program based on the Chronic Care Model to increase therapeutic adherence in patients with secondary prevention for cardiovascular disease. The program includes the following components:~Health Education Sessions: Education on the importance of adherence, understanding the disease, side effects of medications, and their management. It addresses personal beliefs and concerns.~Mobile Phone Reminders: Use of alarms and the ti.care® app to remind patients to take their medications.~Medication Verification: Ensuring that the medications and dosages taken match the prescriptions.~Personalized Dosing Systems (PDS): Helping manage medication intake.~Additional Health Advice: Control of other cardiovascular risk factors and benefits of the Mediterranean diet.
Study: NCT05547503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFA-281
Description: Part 1: AFA-281 will be administered as a single dose at 4 dose levels (TBD) Part 2: AFA-281 will be administered twice daily for 14 - 21 days at 3 dose levels (TBD)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AFA-281
Description: Part 1: AFA-281 will be administered as a single dose at 4 dose levels (TBD) Part 2: AFA-281 will be administered twice daily for 14 - 21 days at 3 dose levels (TBD)
Study: NCT05722821

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypopressive intervention
Description: Hypopressive abdominal gymnastics is based on a basic level hypopressive exercise program that will be:~* A duration of 12 weeks with a frequency of 2 sessions a week and lasting 45 minutes each. Hypopressive abdominal exercises will be performed individually adapted to the capacity of the participant.~* There will be an initial anatomical training of the muscles involved in carrying out the exercise and practice in the respiratory technique for a duration of 15 minutes. Afterwards, hypopressive exercises will begin for 20-30 minutes, changing positions if possible.
Study: NCT05804552

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dorsal genital nerve stimulation
Description: Two types of stimulation electrodes will be used: UCon Patch Electrodes (InnoCon Medical ApS, Denmark) and ValuTrodes/EconoStim Electrodes (5x5 cm, Axelgaard Manufacturing Co. Ltd., United States). The UCon Patch Electrode acts as a cathode and will be placed on the clitoris. The ValuTrode/EconoStim acts as an anode and will be placed on the lower abdomen. The continuous stimulation consists of a train of single pulses provided continuously with a frequency of 20 Hz and a pulse duration of 200 μs. The burst stimulus pattern consists of a train of bursts. The length of the train is 10 s and will consist of 20-30 bursts/s. One burst consists of 5 identical square pulses (monophasic). The inter-pulse interval is 4 ms (time between the onset of 2 consecutive pulses) while a pulse duration of 200 μs will be used.
Study: NCT06251323

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iPATH implementation approach
Description: A multi-level, multi-component, customized, standardized, technology enabled, person-centered, and team-based care practice transformation strategy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iPATH implementation approach
Description: A multi-level, multi-component, customized, standardized, technology enabled, person-centered, and team-based care practice transformation strategy.
Study: NCT04726514

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SleepFlex
Description: SleepFlex Program
Study: NCT04946071

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Arts-based HIV stigma intervention
Description: The intervention will consist of 2-hour weekly sessions offered to students in participating schools. HIV-related stigma will be addressed by providing key information related to HIV and stigma, facilitating the acquisition of coping skills, and utilizing local cultural practices facilitated by Elders using creative methods to shift existing social and cultural norms that produce and perpetuate stigmatization. Specific intervention activities will include three interrelated activities. The core 2-hour weekly session will cover (1) transformative educational activities; (2) arts-based activities; (3) a summative activity consisting of (3) participatory theatre activites.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Arts-based HIV stigma intervention
Description: The intervention will consist of 2-hour weekly sessions offered to students in participating schools. HIV-related stigma will be addressed by providing key information related to HIV and stigma, facilitating the acquisition of coping skills, and utilizing local cultural practices facilitated by Elders using creative methods to shift existing social and cultural norms that produce and perpetuate stigmatization. Specific intervention activities will include three interrelated activities. The core 2-hour weekly session will cover (1) transformative educational activities; (2) arts-based activities; (3) a summative activity consisting of (3) participatory theatre activites.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Arts-based HIV stigma intervention
Description: The intervention will consist of 2-hour weekly sessions offered to students in participating schools. HIV-related stigma will be addressed by providing key information related to HIV and stigma, facilitating the acquisition of coping skills, and utilizing local cultural practices facilitated by Elders using creative methods to shift existing social and cultural norms that produce and perpetuate stigmatization. Specific intervention activities will include three interrelated activities. The core 2-hour weekly session will cover (1) transformative educational activities; (2) arts-based activities; (3) a summative activity consisting of (3) participatory theatre activites.
Study: NCT05031962

Intervention type: DEVICE
Intervention: CELLIS Breast (Porcine Acellular Dermal Matrix, PADM)
Description: Biological membrane used in breast reconstruction
Study: NCT04844931

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RIC + PostC + Standard PCI
Description: RIC by arm ischemia initiated on hospital admission plus local PostC by re-inflating the angioplasty balloon after re-opening the infarct-related artery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard PCI
Description: Standard PCI
Study: NCT05810181

Intervention type: OTHER
Intervention: Interview
Description: The following three groups of stakeholders will be interviewed to assess the beliefs, attitudes, and informational needs around gene therapy for rare pediatric diseases:~(1) patients and families of children with rare genetic diseases who have received gene therapy (to assess their perspectives and understand their informational needs around participating in a clinical trial using gene therapy), (2) patients and families of children with rare genetic diseases who were offered but have decided against receiving gene therapy or ultimately did not qualify for a trial (to elicit feedback and to evaluate whether their informational needs and communication expectations about participating in a clinical trial using gene therapy were met), and (3) healthcare workers who provide care to patients receiving gene therapy (to assess their perspective regarding patient/family needs for gene therapy education and communication).

Intervention type: OTHER
Intervention: Interview
Description: The following three groups of stakeholders will be interviewed to assess the beliefs, attitudes, and informational needs around gene therapy for rare pediatric diseases:~(1) patients and families of children with rare genetic diseases who have received gene therapy (to assess their perspectives and understand their informational needs around participating in a clinical trial using gene therapy), (2) patients and families of children with rare genetic diseases who were offered but have decided against receiving gene therapy or ultimately did not qualify for a trial (to elicit feedback and to evaluate whether their informational needs and communication expectations about participating in a clinical trial using gene therapy were met), and (3) healthcare workers who provide care to patients receiving gene therapy (to assess their perspective regarding patient/family needs for gene therapy education and communication).

Intervention type: OTHER
Intervention: Interview
Description: The following three groups of stakeholders will be interviewed to assess the beliefs, attitudes, and informational needs around gene therapy for rare pediatric diseases:~(1) patients and families of children with rare genetic diseases who have received gene therapy (to assess their perspectives and understand their informational needs around participating in a clinical trial using gene therapy), (2) patients and families of children with rare genetic diseases who were offered but have decided against receiving gene therapy or ultimately did not qualify for a trial (to elicit feedback and to evaluate whether their informational needs and communication expectations about participating in a clinical trial using gene therapy were met), and (3) healthcare workers who provide care to patients receiving gene therapy (to assess their perspective regarding patient/family needs for gene therapy education and communication).
Study: NCT06520878

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NANO-PSO (pomegranate seed oil)
Description: NANO-PSO administered orally, 2 capsules, equivalent to 640 mg of pomegranate seed oil, every 24 hours in the morning with food.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered orally, 2 capsules, equivalent to 640 mg of mineral oil, every 24 hours in the morning with food.
Study: NCT06539637

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: OMIDRIA (*Registered Product) {10.16 mg/mL (1% w/v) of phenylephrine and 2.88 mg/mL (0.3% w/v) of ketorolac}
Description: 10.16 mg/mL (1% w/v) of phenylephrine {Generic Name: Biorphen} (Adrenergic Receptor Agonist) and 2.88 mg/mL (0.3% w/v) of ketorolac {Generic Name: TORADOL} (Nonsteroidal Anti-inflammatory) - via intracameral delivery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Tromethamine {TORADOL} (0.5%) - Topical Eyedrop
Description: Topical ketorolac tromethamine {TORADOL, Nonsteroidal Anti-inflammatory} (0.5%) administered 4 times daily for the 3 days leading up to surgery. The last drop is to be given at least 2 hours prior to surgery.
Study: NCT06338189

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The 5Ad Diet
Description: Participants are to follow the 5Ad diet.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The 5Ad Diet
Description: Participants are to follow the 5Ad diet.
Study: NCT05039268

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3K3A-APC Protein
Description: 3K3A-APC with intravenous dosing of five doses of either 15mg or 30mg at 12 hourly interval. The first 8 patients will receive 15mg dose, and the next 8 patients will receive 30mg dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3K3A-APC Protein
Description: 3K3A-APC with intravenous dosing of five doses of either 15mg or 30mg at 12 hourly interval. The first 8 patients will receive 15mg dose, and the next 8 patients will receive 30mg dose.
Study: NCT06338189

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The Low FODMAP Diet
Description: Participants are to follow the active phase of the Low FODMAP diet.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The Low FODMAP Diet
Description: Participants are to follow the active phase of the Low FODMAP diet.
Study: NCT05801991

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurolens
Description: neurolens® is a type of spectacle lens that uses contoured prism to alleviate vergence demands and fatigue at near and, therefore, encourages comfortable vision.8 This spectacle design uses the neurolens® Measurement Device (nMD) to measure eye alignment and determine the spectacle lenses that are uniquely designed for each wearer.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo spectacle lens
Description: Plano (no power) spectacle lenses will be assigned to the placebo group